Showing results (921-930 of 1,795) with videos related to

Sort By:
Pageof 180
Mabs|June 17, 2020
Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17ASongmao Zheng, Fang Shen, Brian Jones, et al.
Mabs|April 21, 2020
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?Evelien Moorkens, Arnold G Vulto, Isabelle Huys
Mabs|June 13, 2015
Processing of complex N-glycans in IgG Fc-region is affected by core fucosylationAlexandra Castilho, Clemens Gruber, Andreas Thader, et al.
Mabs|July 18, 2015
Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologicsRichard S Rogers, Nancy S Nightlinger, Brittney Livingston, et al.
Mabs|July 17, 2015
Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRnTianlei Ying, Yanping Wang, Yang Feng, et al.
Mabs|May 29, 2015
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-lifeColby A Souders, Stuart C Nelson, Yang Wang, et al.
Mabs|May 24, 2021
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodiesRomain Rouet, Ohan Mazigi, Gregory J Walker, et al.
Mabs|May 25, 2021
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion proteinTakuo Suzuki, Noritaka Hashii, Minoru Tada, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Mabs|August 4, 2021
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodiesMaxwell A Stefan, Yooli K Light, Jennifer L Schwedler, et al.
Pageof 180